Entrada Therapeutics (TRDA) Total Liabilities (2020 - 2026)

Entrada Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 6.58% year-over-year to $64.7 million; the TTM figure through Mar 2026 stood at $64.7 million (down 6.58% YoY), while the FY2025 annual figure was $71.2 million, down 27.04% from the prior year.
• Total Liabilities for Q1 2026 stood at $64.7 million, down from $71.2 million in the prior quarter.
• The five-year high for Total Liabilities was $287.1 million in Q2 2023, with the low at $39.3 million in Q1 2022.
• The 5-year median for Total Liabilities is $72.2 million (2025), against an average of $125.2 million.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 619.88% in 2023, then plunged 71.34% in 2025.
• Entrada Therapeutics' Total Liabilities stood at $39.5 million in 2022, then jumped by 474.23% to $226.8 million in 2023, then slumped by 56.95% to $97.6 million in 2024, then declined by 27.04% to $71.2 million in 2025, then retreated by 9.24% to $64.7 million in 2026.
• Business Quant data shows TRDA's Total Liabilities at $64.7 million in Q1 2026, $71.2 million in Q4 2025, and $72.2 million in Q3 2025.